Ensysce Biosciences CEO Lynn Kirkpatrick to Become Chief Operating Officer After Annual Meeting

PUBT · 22h ago
Ensysce Biosciences CEO Lynn Kirkpatrick to Become Chief Operating Officer After Annual Meeting
  • Ensysce Biosciences President James Morrisson will become CEO immediately following the annual stockholder meeting scheduled for December 14, 2026.
  • On October 29, 2026, CEO Lynn Kirkpatrick agreed to relinquish that title and become chief operating officer immediately following the meeting.
  • Both leadership changes will be delayed if the annual meeting is postponed.
  • Director Will Chang intends to resign from the board following the annual meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-049906), on November 04, 2026, and is solely responsible for the information contained therein.